In vitro selection and analysis of human immunodeficiency virus Type 1 resistant to derivatives of β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine

被引：13

作者：

Hammond, JL

Parikh, UM

Koontz, DL

Schlueter-Wirtz, S

Chu, CK

Bazmi, HZ

Schinazi, RF

Mellors, JW

机构：

[1] Univ Pittsburgh, Sch Med, Div Infect Dis, Dept Med, Pittsburgh, PA 15261 USA

[2] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA

[3] Vet Affairs Med Ctr, Georgia VA Res Ctr AIDS & HIV Infect, Atlanta, GA 30033 USA

[4] Univ Georgia, Coll Pharm, Athens, GA 30602 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 09期

关键词：

D O I：

10.1128/AAC.49.9.3930-3932.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Serial passage of human immunodeficiency virus type 1 in MT-2 cells in increasing concentrations of the D-and L-enantiomers of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (d4FC) resulted in the selection of viral variants with reverse transcriptase substitutions M184I or M184V for L-d4FC and I63L, K65R, K70N, K70E, or R172K for D-d4FC. Phenotypic analysis of site-directed mutants defined the role of these mutations in reducing susceptibility to L- or D-d4FC.

引用

收藏

页码：3930 / 3932

页数：3

相关论文

共 15 条

[1] In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-β-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine [J].

Bazmi, HZ ;

Hammond, JL ;

Cavalcanti, SCH ;

Chu, CK ;

Schinazi, RF ;

Mellors, JW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1783-1788

[2]

Geleziunas Romas, 2003, Antiviral Chemistry & Chemotherapy, V14, P49

[3] Structure of a covalently trapped catalytic complex of HIV-I reverse transcriptase: Implications for drug resistance [J].

Huang, HF ;

Chopra, R ;

Verdine, GL ;

Harrison, SC .

SCIENCE, 1998, 282 (5394) :1669-1675

[4] The role of genotypic heterogeneity in wild type virus populations on the selection of nonnucleoside reverse transcriptase inhibitor-resistant viruses [J].

Kinjerski, TL ;

Buckheit, RW .

ANTIVIRAL RESEARCH, 1997, 33 (02) :109-115

[5] In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097 [J].

Kleim, JP ;

Winkler, I ;

Rosner, M ;

Kirsch, R ;

RubsamenWaigmann, H ;

Paessens, A ;

Riess, G .

VIROLOGY, 1997, 231 (01) :112-118

[6] Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy-2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro [J].

Lin, TS ;

Luo, MZ ;

Liu, MC ;

Zhu, YL ;

Gullen, E ;

Dutschman, GE ;

Cheng, YC .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (09) :1757-1759

[7] NOVEL MUTATIONS IN REVERSE-TRANSCRIPTASE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REDUCE SUSCEPTIBILITY TO FOSCARNET IN LABORATORY AND CLINICAL ISOLATES [J].

MELLORS, JW ;

BAZMI, HZ ;

SCHINAZI, RF ;

ROY, BM ;

HSIOU, Y ;

ARNOLD, E ;

WEIR, J ;

MAYERS, DL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) :1087-1092

[8] Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type I reverse transcriptase [J].

Meyer, PR ;

Matsuura, SE ;

Tolun, AA ;

Pfeifer, I ;

So, AG ;

Mellors, JW ;

Scott, WA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1540-1545

[9] In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase [J].

Parikh, UM ;

Koontz, DL ;

Chu, CK ;

Schinazi, RF ;

Mellors, JW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :1139-1144

[10]

Ray Adrian S., 2003, Antiviral Chemistry & Chemotherapy, V14, P115